Skip to main content
. 2021 Apr 20;12:667474. doi: 10.3389/fphar.2021.667474

FIGURE 7.

FIGURE 7

Inhibitory effects of MAZ51 on the proliferation of human prostate cancer cells. The effects of MAZ51 on the cell viability and proliferation of human prostate epithelial PrEC cells and prostate cancer LNCaP, PC-3, and DU145 cells using MTT and BrdU assays, respectively. (A) Time-dependent cell growth of PrEC, LNCaP, PC-3, and DU145 cells (n = 9–16). (B) The effects of MAZ51 for 48 h on the viability of PrEC, LNCaP, PC-3, and DU145 cells (n = 8–34). The IC50 values of MAZ51 on the viabilities of PrEC, LNCaP, PC-3, and DU145 cells were 7.0, 6.0, 2.7, and 3.8 μM, respectively. (C) The effects of 100 nM GSK690693 (an Akt inhibitor) for 48 h on the viability of PrEC, LNCaP, PC-3, and DU145 cells (n = 12–18). (D) The effects of VEGFR2 Kinase Inhibitor I for 48 h on the viability of PrEC, LNCaP, PC-3, and DU145 cells (n = 12–24). (E) The effects of MAZ51 for 48 h on the proliferation of PC-3 cells (n = 12). (F) The effects of 50 and 100 nM VEGFR-3 siRNA for 48 h on the proliferation of PC-3 cells (n = 16–24). Data are presented as means ± S.D. *p < 0.05, **p < 0.01 vs. 6 h, 0 μM drug, or control siRNA; # p < 0.05, ## p < 0.01 vs. PrEC cells (Scheffé’s test following ANOVA).